This is a phase 2 clinical study exploring a potential new treatment to improve outcomes for patients with platinum-resistant HGOC.
Acceptance Requirements
Confirmed diagnosis of platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal or fallopian tube
Must be able to sit or recline with limited movement for approximately 6 hours and be able to attend required study visits
Participants must have received prior treatment with bevacizumab